Purpose: To estimate the risk of malignant transformation of a choroidal nevus in the white population.
Design: Systematic literature review.
Methods: A literature review was performed to obtain data on the prevalence of choroidal nevi in the white population. Data from studies that used indirect ophthalmoscopy or otherwise corrected data to include the entire fundus were selected. Only studies reporting on the United States population were included. The number of affected individuals was estimated using 2000 U.S. census data. The estimate of annual incident choroidal melanoma cases in the corresponding age- and race-matched population was calculated using the Surveillance, Epidemiology, and End Result database (1973-2000). Average annual age-specific incidence rates for 1973 to 2000 for each of the 5-year age groups (adjusted for the U.S. 2000 population) were calculated and applied to the corresponding census data. The ratio of numbers of affected individuals with choroidal melanoma and choroidal nevi gave the annual rate of malignant transformation of a choroidal nevus.
Main Outcome Measures: Annual rate of malignant transformation of a choroidal nevus in the white population of the U.S.
Results: The prevalence of choroidal nevus in the white U.S. population ranged from 4.6% to 7.9%. It was estimated that, on average, 8864625 individuals in the U.S. had a choroidal nevus. The number of individuals with choroidal melanoma in the corresponding age- and race-matched population ranged from 989 to 1008 (mean, 1002). The annual rate of malignant transformation of a choroidal nevus was estimated to be 1 in 8845.
Conclusions: If it is assumed that all choroidal melanomas arise from preexisting nevi, then the published data suggest a low rate (1/8845) of malignant transformation of a choroidal nevus in the U.S. white population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ophtha.2005.06.011 | DOI Listing |
Semin Ophthalmol
January 2025
Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA.
Purpose: Standardized data collection is needed to improve research for rare diseases. In this manuscript, we describe our experience establishing the Prospective Ocular Tumor Study (POTS).
Methods: The ongoing POTS captures all patients with an ocular tumor seen on the Ocular Oncology Service at Mayo Clinic Rochester and collects patient demographics, tumor features, treatment, and outcomes.
Lasers Med Sci
January 2025
Department of Ophthalmology, Ankara University School of Medicine, Ankara, Turkey.
The aim of the study was todescribe the clinical features, optical coherence tomography (OCT) and fundus autofluorescence (FAF) imaging in patients with choroidal and retinal tumors. Ninety eyes of 89 patients with treatment-naive macular, midperipheral, and juxtapapillary choroidal and retinal tumors were retrospectively included in the study. All patients underwent a complete ophthalmic examination, B-mode ultrasonography, OCT, and FAF imaging.
View Article and Find Full Text PDFOphthalmol Retina
January 2025
Bay Area Retina Associates, Walnut Creek, California.
Ophthalmol Sci
November 2024
Liverpool Ocular Oncology Research Group, Department of Eye and Vision Science, Institute of Life Course and Medical Sciences (ILCaMS), University of Liverpool, Liverpool, United Kingdom.
Purpose: Testing the validity of a self-supervised deep learning (DL) model, RETFound, for use on posterior uveal (choroidal) melanoma (UM) and nevus differentiation.
Design: Case-control study.
Subjects: Ultrawidefield fundoscopy images, both color and autofluorescence, were used for this study, obtained from 4255 patients seen at the Liverpool Ocular Oncology Center between 1995 and 2020.
J Fr Ophtalmol
January 2025
Service d'ophtalmologie, hôpital Claude-Huriez, CHU de Lille, rue Michel-Polonowski, Lille, France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!